TLDR
- Amylyx stock jumped around 21% in pre-market trading after its GLP-1 drug avexitide hit both primary and secondary endpoints in a Phase 3 trial
- The trial showed patients had 55% fewer severe hypoglycemic events compared to placebo
- Mizuho raised its price target on AMLX to $30 from $24, keeping an Outperform rating
- Avexitide holds FDA Breakthrough Therapy Designation and Orphan Drug Designation
- A potential commercial launch is targeted for 2027, with early NDA preparations already underway
Amylyx Pharmaceuticals stock jumped roughly 21% in pre-market trading on Tuesday after the company announced that avexitide, its investigational GLP-1 receptor antagonist, succeeded in a late-stage clinical trial. The stock hit a pre-market price of $26.76, clearing its prior 52-week high of $24.60.
Amylyx Pharmaceuticals, Inc., AMLX
The Phase 3 LUCIDITY trial was a 16-week, multicenter, randomized, double-blind, placebo-controlled study enrolling 78 participants. It was designed to test avexitide in patients with post-bariatric hypoglycemia, a condition that causes dangerous drops in blood sugar after eating, often appearing years after weight-loss surgery.
$AMLX PHASE 3 TRIAL HITS PRIMARY ENDPOINT
Amylyx said avexitide reduced Level 2 and Level 3 hypoglycemic events by 55% versus placebo in its Phase 3 LUCIDITY trial for post-bariatric hypoglycemia, with p=0.000003.
The trial also met all secondary endpoints and showed no…
— Wall St Engine (@wallstengine) August 18, 2026
The trial hit its primary endpoint, which had been agreed upon with regulators in advance. Patients taking avexitide had 55% fewer severe hypoglycemic events than those on placebo.
The drug also cleared every secondary benchmark. That includes results from both self-monitored fingerstick testing and continuous glucose monitoring.
Avexitide works differently from GLP-1 drugs like Wegovy and Zepbound. Rather than mimicking the GLP-1 hormone to lower blood sugar, it blocks GLP-1 receptors on the pancreas, stopping the hormone from over-signaling after meals.
Mizuho Raises Price Target
Mizuho raised its price target on AMLX to $30 from $24 ahead of the readout, keeping its Outperform rating. The firm also named the stock a top 2026 pick and estimated a potential move of $10 to $15 higher from prior levels if the Phase 3 came back positive.
Avexitide carries both FDA Breakthrough Therapy Designation and Orphan Drug Designation, which could support a faster path to regulatory approval.
Amylyx said early NDA-readiness preparations are already underway. A potential commercial launch is targeted for 2027.
Market Context
The move came on a rough day for the broader market. The Nasdaq fell 1.2% and the S&P 500 slipped 0.5% in pre-market trading. The biotech sector also faced headwinds on the day.
Amylyx hosted a senior management conference call at 8:00 a.m. ET on Tuesday to discuss the trial findings.
The company had previously guided for a broader Q3 2026 timeline for the data release. Tuesday’s announcement pulled that forward.
AMLX’s pre-market price of $26.76 pushed the stock well above its previous 52-week high of $24.60.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
